Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JUVÉDERM VOLUX XC
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous, Supraperiosteal
01
Overview
JUVÉDERM VOLUX XC is a sterile, biodegradable, non-pyrogenic, viscoelastic gel implant used as a dermal filler. It consists of hyaluronic acid (HA) produced by Streptococcus species of bacteria and crosslinked with 1,4-butanediol diglycidyl ether (BDDE), formulated at a concentration of 25 mg/mL with 0.3% w/w lidocaine in a physiologic buffer[1][2][3][4]. The product is manufactured using proprietary VYCROSS technology to create a smooth and dense gel that provides structure and volume when injected subcutaneously or supraperiosteally. Its primary indication is for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition[1][2][3]. The mechanism involves physical augmentation—restoring lost volume and contouring facial features by providing structural support under the skin. Lidocaine is included to reduce pain during injection[1][2].
- Brand names
- JUVÉDERM VOLUX XC
- Other names
- Juvederm VoluxJuvederm Volux XCJuvederm Volux™ XC
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on JUVÉDERM VOLUX XC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JUVÉDERM VOLUX XC.